Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 35


HIV-1 pol replication capacity predicts disease progression.

Daar ES, Kesler KL, Wrin T, Petropoulo CJ, Bates M, Lail A, Hellmann NS, Gomperts E, Donfield S; Hemophilia Growth and Development Study.

AIDS. 2005 Jun 10;19(9):871-7.


A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575.

Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, Forthal DN, Leedom J, Leibowitz M, McCutchan JA, Richman DD; California Collaborative Treatment Group.

AIDS. 2005 Feb 18;19(3):295-302.


Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance.

Kaplan SS, Ferrari G, Wrin T, Hellmann NS, Tomaras GD, Gryszowka VE, Fiscus SA, Weinhold KJ, Hicks CB.

AIDS Res Hum Retroviruses. 2005 Jan;21(1):13-6.


Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.

Uhlmann EJ, Tebas P, Storch GA, Powderly WG, Lie YS, Whitcomb JM, Hellmann NS, Arens MQ.

J Clin Virol. 2004 Nov;31(3):198-203.


HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.

Demeter LM, Ribaudo HJ, Erice A, Eshleman SH, Hammer SM, Hellmann NS, Fischl MA; AIDS Clinical Trials Group Protocol 388.

Clin Infect Dis. 2004 Aug 15;39(4):552-8. Epub 2004 Jul 30.


Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection.

Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, Busch MP, Petropoulos CJ, Hellmann NS, Kahn JO, Grant RM.

J Infect Dis. 2004 Jul 15;190(2):251-6. Epub 2004 Jun 18.


Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection.

Leigh Brown AJ, Frost SD, Good B, Daar ES, Simon V, Markowitz M, Collier AC, Connick E, Conway B, Margolick JB, Routy JP, Corbeil J, Hellmann NS, Richman DD, Little SJ.

J Virol. 2004 Mar;78(5):2242-6.


Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.

Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, Haubrich RH, St Clair M, Lanier ER, Hellmann NS, Richman DD.

Antivir Ther. 2003 Dec;8(6):489-506. Review.


Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.

Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ.

Antimicrob Agents Chemother. 2004 Feb;48(2):437-43.


Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ.

J Infect Dis. 2003 Oct 1;188(7):992-1000. Epub 2003 Sep 16.


Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.

Sufka SA, Ferrari G, Gryszowka VE, Wrin T, Fiscus SA, Tomaras GD, Staats HF, Patel DD, Sempowski GD, Hellmann NS, Weinhold KJ, Hicks CB.

J Infect Dis. 2003 Apr 1;187(7):1027-37. Epub 2003 Mar 13.


Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population.

Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, Richman DD, Little SJ.

J Infect Dis. 2003 Feb 15;187(4):683-6. Epub 2003 Jan 29.


Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.

Parkin N, Chappey C, Maroldo L, Bates M, Hellmann NS, Petropoulos CJ.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):128-36.


Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.

Shulman NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM, Katzenstein DA.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):121-7.


Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ.

AIDS. 2002 Oct 18;16(15):F41-7.


The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.

Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA; California Collaborative Treatment Group.

AIDS. 2002 Oct 18;16(15):F33-40.


Antiretroviral-drug resistance among patients recently infected with HIV.

Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD.

N Engl J Med. 2002 Aug 8;347(6):385-94.


Time trends in primary HIV-1 drug resistance among recently infected persons.

Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO.

JAMA. 2002 Jul 10;288(2):181-8.


CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy.

Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, Cesar D, Abe K, Hanley MB, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK.

J Infect Dis. 2002 Feb 1;185(3):315-23. Epub 2002 Jan 17.


Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure.

Roland ME, Martin JN, Grant RM, Hellmann NS, Bamberger JD, Katz MH, Chesney M, Franses K, Coates TJ, Kahn JO.

J Infect Dis. 2001 Dec 15;184(12):1608-12. Epub 2001 Dec 3.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk